Literature DB >> 25869219

Vermont responds to its opioid crisis.

Thomas A Simpatico1.   

Abstract

Vermont is one of the more forward-thinking states in the nation with a history of taking groundbreaking approaches to complex social issues. In his Jan 8, 2014 State of the State Address, Vermont Governor Peter Shumlin announced that Vermont was in the midst of an opioid addiction epidemic. Though Vermont had called attention to its opioid crisis, it soon became clear that many other states shared this problem. Economic modeling of expanded access to maintenance therapy with either methadone or buprenorphine is felt to have "high value" because the added health care costs of treatment are offset by reductions in other health care costs that occur when individuals with opioid dependence begin treatment. Moreover, when broader societal costs such as criminal activity and work productivity are included, maintenance treatment is estimated to produce substantial overall savings. Coordinated efforts between the Vermont Department of Health's Division of Alcohol and Drug Abuse Programs (ADAP) and the Department of Vermont Health Access (DVHA-Vermont Medicaid Authority) have resulted in the creation of the Care Alliance for Opioid Addiction (or Hub & Spoke model). Vermont intends to develop a reproducible and exportable model based on cost effective, outcomes driven public policy.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Opioid substitution treatment; Public health; Public policy

Mesh:

Substances:

Year:  2015        PMID: 25869219     DOI: 10.1016/j.ypmed.2015.04.002

Source DB:  PubMed          Journal:  Prev Med        ISSN: 0091-7435            Impact factor:   4.018


  10 in total

1.  Patient perceptions of treatment with medication treatment for opioid use disorder (MOUD) in the Vermont hub-and-spoke system.

Authors:  Richard A Rawson; Traci Rieckmann; Sarah Cousins; Michael McCann; Regina Pearce
Journal:  Prev Med       Date:  2019-07-27       Impact factor: 4.018

2.  Impact of Policy Interventions on Postoperative Opioid Prescribing.

Authors:  Charles D MacLean; Mayo Fujii; Thomas P Ahern; Peter Holoch; Ruby Russell; Ashley Hodges; Jesse Moore
Journal:  Pain Med       Date:  2019-06-01       Impact factor: 3.750

3.  High Mortality Among Patients With Opioid Use Disorder in a Large Healthcare System.

Authors:  Yih-Ing Hser; Larissa J Mooney; Andrew J Saxon; Karen Miotto; Douglas S Bell; Yuhui Zhu; Di Liang; David Huang
Journal:  J Addict Med       Date:  2017 Jul/Aug       Impact factor: 3.702

4.  Process Evaluation of a Community Outpatient Program Treating Substance Use Disorders.

Authors:  James L Sorensen; Jasmin D Llamas
Journal:  J Community Psychol       Date:  2018-05-04

5.  Closing the Medication-Assisted Treatment Gap for Youth With Opioid Use Disorder.

Authors:  Brendan Saloner; Kenneth A Feder; Noa Krawczyk
Journal:  JAMA Pediatr       Date:  2017-08-01       Impact factor: 16.193

6.  Insurance Companies Fighting the Peer Review Empire without any Validity: the Case for Addiction and Pain Modalities in the face of an American Drug Epidemic.

Authors:  K Blum; W Jacobs; E J Modestino; N DiNubile; D Baron; T McLaughlin; D Siwicki; I Elman; M Moran; E R Braverman; P K Thanos; R D Badgaiyan
Journal:  SEJ Surg Pain       Date:  2018-10-04

7.  Why aren't physicians prescribing more buprenorphine?

Authors:  Andrew S Huhn; Kelly E Dunn
Journal:  J Subst Abuse Treat       Date:  2017-04-12

8.  Vermont Hub-and-Spoke Model of Care for Opioid Use Disorder: Development, Implementation, and Impact.

Authors:  John R Brooklyn; Stacey C Sigmon
Journal:  J Addict Med       Date:  2017 Jul/Aug       Impact factor: 3.702

9.  Editorial: 2nd Special Issue on behavior change, health, and health disparities.

Authors:  Stephen T Higgins
Journal:  Prev Med       Date:  2015-08-06       Impact factor: 4.018

10.  Barriers for Implementing the Hub and Spoke Model to Expand Medication for Opioid Use Disorder: A Case Study of Montana.

Authors:  Brandn Green; Danielle Christine Rhubart; Matthew R Filteau
Journal:  Subst Abuse       Date:  2021-08-30
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.